Nvidia’s venture arm, NVentures, disclosed ownership of 833,325 shares in Generate:Biomedicines, valued at approximately $10.4 million according to Nvidia’s latest 13F filing in May 2026. Generate, which trades on the Nasdaq under the ticker GENB, is building an AI-powered platform designed to automate the generation and optimization of therapeutic proteins, essentially trying to compress years of drug discovery into months.
What Generate:Biomedicines actually does
The company uses generative AI models to design proteins and drug candidates from scratch. Generate’s pipeline is already well past the theoretical stage. The company has a Phase 3 clinical trial underway for severe asthma, which is the final stage of testing before seeking regulatory approval. It also has multiple oncology candidates that have received FDA Fast Track designation, a status reserved for treatments addressing serious conditions with unmet medical needs.
The company has raised roughly $700 million in total funding since its founding. NVentures first got involved during Generate’s $273 million Series C round, which closed in September 2023 and included participation from Amgen, one of the world’s largest biotech companies. Generate then went public with a Nasdaq IPO in February 2026.
